SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19

Clinical trial NCT05629962 · COMPLETED

Trial details

NCT number: NCT05629962
Sponsor: Atea Pharmaceuticals, Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection)COVID-19

Start date: 2022-11-25
Primary completion: 2024-04-25
Enrollment: 2285

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.